Soleo Health Selected By Bio Products Laboratory (BPL) To Dispense Coagadex®
The first and only treatment for hereditary factor X deficiency
The first and only treatment for hereditary factor X deficiency
SHARON HILL, Pa., Oct. 26, 2015 /PRNewswire/ -- Soleo Health, "Soleo," an innovative leader in specialty infusion, announced today that it has been selected by Bio Products Laboratory (BPL) to dispense Coagadex® (Coagulation Factor X, Human). On October 20, 2015, Coagadex was approved by the U.S. Food and Drug Administration for the treatment of adults and children (aged 12 years and above) with hereditary factor X deficiency for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with mild hereditary factor X deficiency.
Logo - http://photos.prnewswire.com/prnh/20151026/280368LOGO
Hereditary factor X deficiency is a rare bleeding disorder that affects approximately 300-600 patients in the U.S. Affected individuals often have inadequate amounts of circulating factor X, an important component of the coagulation system. Factor X deficient patients are at increased risk of bleeding and need to be managed similarly to hemophilia patients.
"We are excited to offer patients with hereditary factor X deficiency and prescribing physicians the option of Coagadex as the first and only treatment option specifically developed and approved for this rare condition," said Craig Vollmer, Executive Vice President of Strategic Development. "By selecting Soleo Health to dispense this new therapy, BPL recognizes Soleo's commitment to providing exceptional patient care and services to the bleeding disorders community."
Like all of Soleo's proprietary therapy management programs, Coagadex will be managed by a team of experienced clinicians and support personnel. "Our pharmacists, registered nurses and reimbursement teams have completed extensive training on Coagadex dosing and administration and are prepared to provide treatment and clinical education to patients who make the decision with their physician to infuse Coagadex," Vollmer added.
Please see the full prescribing information for Coagadex at www.coagadex.com
About Soleo Health
Soleo Health is an innovative national provider of specialty home and alternate-site infusion services. Its team of experienced clinicians provides exceptional care in managing complex disease states through comprehensive pharmacy, nursing, education, and therapy management programs driven by technology. With a consultative approach to customer service, Soleo ensures patients' financial, clinical and administrative needs are met by compassionate and caring associates, resulting in greater customer satisfaction.
Soleo Health serves the United States through locations across the country and is accredited by The Joint Commission and URAC. For more information, visit www.soleohealth.com.
CONTACT:
Craig Vollmer |
Barbara Prosser, RPh |
Executive Vice President, Strategic Development |
Vice President, Clinical Services |
610.586.2340 |
610.586.2340 |
SOURCE Soleo Health
Share this article